JP7450888B2 - がんにおける免疫療法との併用タキソイドナノエマルジョン - Google Patents

がんにおける免疫療法との併用タキソイドナノエマルジョン Download PDF

Info

Publication number
JP7450888B2
JP7450888B2 JP2020557314A JP2020557314A JP7450888B2 JP 7450888 B2 JP7450888 B2 JP 7450888B2 JP 2020557314 A JP2020557314 A JP 2020557314A JP 2020557314 A JP2020557314 A JP 2020557314A JP 7450888 B2 JP7450888 B2 JP 7450888B2
Authority
JP
Japan
Prior art keywords
oil
cancer
sbt
tumor
dha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020557314A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517906A (ja
JP2021517906A5 (enExample
Inventor
イー． イーガン、ジェイムズ
アミジ、マンスール
尾島　巌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targagenix Inc
Original Assignee
Targagenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targagenix Inc filed Critical Targagenix Inc
Publication of JP2021517906A publication Critical patent/JP2021517906A/ja
Publication of JP2021517906A5 publication Critical patent/JP2021517906A5/ja
Priority to JP2023202505A priority Critical patent/JP2024023463A/ja
Application granted granted Critical
Publication of JP7450888B2 publication Critical patent/JP7450888B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020557314A 2017-12-20 2018-12-19 がんにおける免疫療法との併用タキソイドナノエマルジョン Active JP7450888B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023202505A JP2024023463A (ja) 2017-12-20 2023-11-30 がんにおける免疫療法との併用タキソイドナノエマルジョン

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762608015P 2017-12-20 2017-12-20
US62/608,015 2017-12-20
PCT/US2018/066465 WO2019126302A2 (en) 2017-12-20 2018-12-19 Combination taxoid nanoemulsion with immunotherapy in cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023202505A Division JP2024023463A (ja) 2017-12-20 2023-11-30 がんにおける免疫療法との併用タキソイドナノエマルジョン

Publications (3)

Publication Number Publication Date
JP2021517906A JP2021517906A (ja) 2021-07-29
JP2021517906A5 JP2021517906A5 (enExample) 2022-01-11
JP7450888B2 true JP7450888B2 (ja) 2024-03-18

Family

ID=66815378

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020557314A Active JP7450888B2 (ja) 2017-12-20 2018-12-19 がんにおける免疫療法との併用タキソイドナノエマルジョン
JP2023202505A Abandoned JP2024023463A (ja) 2017-12-20 2023-11-30 がんにおける免疫療法との併用タキソイドナノエマルジョン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023202505A Abandoned JP2024023463A (ja) 2017-12-20 2023-11-30 がんにおける免疫療法との併用タキソイドナノエマルジョン

Country Status (6)

Country Link
US (2) US11497713B2 (enExample)
EP (1) EP3752130A4 (enExample)
JP (2) JP7450888B2 (enExample)
CN (1) CN112996501A (enExample)
CA (1) CA3121615A1 (enExample)
WO (1) WO2019126302A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7518604B2 (ja) * 2016-06-07 2024-07-18 タルガジェニックス，インコーポレイテッド タキソイド薬物のナノエマルション組成物、並びに標的癌細胞及び癌幹細胞に対するその使用方法
CA3121615A1 (en) * 2017-12-20 2019-06-27 Targagenix, Inc. Combination taxoid nanoemulsion with immunotherapy in cancer
CN116173094A (zh) * 2023-03-15 2023-05-30 中南大学湘雅二医院 一种杜仲籽油在制备抗癌药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511187A (ja) 1996-05-22 2000-08-29 ニューロメディカ インコーポレーテッド シス―ドコサヘキサエン酸およびパクリタクセルの複合体
JP2007510648A (ja) 2003-10-30 2007-04-26 ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク タキソイド−脂肪酸コンジュゲート及びその医薬組成物
JP2017513931A (ja) 2014-04-03 2017-06-01 インビクタス オンコロジー ピーヴィティー．リミテッド 超分子コンビナトリアル治療薬
WO2017214260A1 (en) 2016-06-07 2017-12-14 Targagenix, Inc. Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
JP6042527B2 (ja) * 2012-04-04 2016-12-14 ハロザイム インコーポレイテッド 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療
CA3121615A1 (en) * 2017-12-20 2019-06-27 Targagenix, Inc. Combination taxoid nanoemulsion with immunotherapy in cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000511187A (ja) 1996-05-22 2000-08-29 ニューロメディカ インコーポレーテッド シス―ドコサヘキサエン酸およびパクリタクセルの複合体
JP2007510648A (ja) 2003-10-30 2007-04-26 ザ リサーチ ファウンデーション オブ ステイト ユニヴァーシティ オブ ニューヨーク タキソイド−脂肪酸コンジュゲート及びその医薬組成物
JP2017513931A (ja) 2014-04-03 2017-06-01 インビクタス オンコロジー ピーヴィティー．リミテッド 超分子コンビナトリアル治療薬
WO2017214260A1 (en) 2016-06-07 2017-12-14 Targagenix, Inc. Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Letters，2017年10月，Vol.406，pp.71-80

Also Published As

Publication number Publication date
US20190183796A1 (en) 2019-06-20
US12186428B2 (en) 2025-01-07
JP2021517906A (ja) 2021-07-29
CN112996501A (zh) 2021-06-18
JP2024023463A (ja) 2024-02-21
WO2019126302A2 (en) 2019-06-27
WO2019126302A3 (en) 2020-03-26
US20230082272A1 (en) 2023-03-16
EP3752130A2 (en) 2020-12-23
CA3121615A1 (en) 2019-06-27
US11497713B2 (en) 2022-11-15
EP3752130A4 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
Guimarães et al. Nanoparticles for immune cytokine TRAIL-based cancer therapy
Zhang et al. A siRNA-assisted assembly strategy to simultaneously suppress “self” and upregulate “eat-me” signals for nanoenabled chemo-immunotherapy
Valcourt et al. Nanoparticle-mediated co-delivery of Notch-1 antibodies and ABT-737 as a potent treatment strategy for triple-negative breast cancer
Luo et al. Nanoparticle-mediated CD47-SIRPα blockade and calreticulin exposure for improved cancer chemo-immunotherapy
JP2024023463A (ja) がんにおける免疫療法との併用タキソイドナノエマルジョン
Nesbitt et al. Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer
Zhou et al. Immunotherapy strategy targeting programmed cell death ligand 1 and CD73 with macrophage-derived mimetic nanovesicles to treat bladder cancer
Gilabert-Oriol et al. Liposomal formulations to modulate the tumour microenvironment and antitumour immune response
JP7330994B2 (ja) 治療用ナノ生物学的組成物による訓練免疫の促進
Shetab Boushehri et al. A nanoparticle-based approach to improve the outcome of cancer active immunotherapy with lipopolysaccharides
Raikwar et al. Opportunities in combinational chemo-immunotherapy for breast cancer using nanotechnology: an emerging landscape
Ahmad et al. DHA-SBT-1214 taxoid nanoemulsion and anti–PD-L1 antibody combination therapy enhances antitumor efficacy in a syngeneic pancreatic adenocarcinoma model
JP2020511147A (ja) 薬剤負荷ナノ粒子が表面に結合したｃａｒ ｔ細胞の養子移入およびその使用
CN109562065A (zh) 靶向癌细胞和癌干细胞的紫杉烷类药物的纳米乳剂组合物及其使用方法
Kaur et al. Nanotechnology for boosting ovarian cancer immunotherapy
JP2022116289A (ja) ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
Kanp et al. Exploring the Potential of Nanocarriers for Cancer Immunotherapy: Insights into Mechanism, Nanocarriers, and Regulatory Perspectives
Nadukkandy et al. Tracing new landscapes in the arena of nanoparticle-based cancer immunotherapy
US20230285295A1 (en) Combined pharmaceutical formulation comprising gemcitabine-containing liposome composition and immune checkpoint inhibitor
Bie et al. Tumor-Repopulating Cell-Derived Microparticle-Based Therapeutics Amplify the Antitumor Effect through Synergistic Inhibition of Chemoresistance and Immune Evasion
Ngo et al. Nano-immunotherapy: Merging immunotherapy precision with nanomaterial delivery
Reda et al. Development of novel immunotherapy based on nanoparticle co-delivering PLK1 and PD-L1 inhibitors for lung cancer treatment
Cremolini et al. Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. Nanomaterials 2021, 11, 661
Zhang Combinatorial Therapy for Solid Tumor.
HK40041777B (en) Combination medication containing liposome composition encapsulating drug and immune checkpoint inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240227

R150 Certificate of patent or registration of utility model

Ref document number: 7450888

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150